메뉴 건너뛰기




Volumn 16, Issue 4, 2007, Pages 385-392

Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: Observational study

Author keywords

Fire and forget; Statin prescribing; Treat to target

Indexed keywords

ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIAC GLYCOSIDE; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; PRAVASTATIN; SIMVASTATIN;

EID: 34247480862     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1297     Document Type: Article
Times cited : (33)

References (26)
  • 1
    • 0027987849 scopus 로고
    • Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
    • Pedersen TR, Kjekshus J, Berg K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
    • (1994) Lancet , vol.344 , pp. 1383-1389
    • Pedersen, T.R.1    Kjekshus, J.2    Berg, K.3
  • 2
    • 0028883828 scopus 로고
    • Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
    • Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
    • (1995) N Engl J Med , vol.333 , pp. 1301-1307
    • Shepherd, J.1    Cobbe, S.M.2    Ford, I.3
  • 3
    • 0342981862 scopus 로고    scopus 로고
    • The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
    • Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009.
    • (1996) N Engl J Med , vol.335 , pp. 1001-1009
    • Sacks, F.M.1    Pfeffer, M.A.2    Moye, L.A.3
  • 4
    • 0032487931 scopus 로고    scopus 로고
    • Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
    • Tonkin A, Aylward P, Colquhoun D, et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-1357.
    • (1998) N Engl J Med , vol.339 , pp. 1349-1357
    • Tonkin, A.1    Aylward, P.2    Colquhoun, D.3
  • 5
    • 0037031061 scopus 로고    scopus 로고
    • MRC/BHF Heart Protection Study of cholesterol lowering with sinivastatin in 20536 high-risk individuals: A randomized placebo-controlled trial
    • Heart Protection Study Group
    • Heart Protection Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with sinivastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22.
    • (2002) Lancet , vol.360 , pp. 7-22
  • 6
    • 0037420492 scopus 로고    scopus 로고
    • Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomized controlled trial
    • Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 1149-1158.
    • (2003) Lancet , vol.361 , pp. 1149-1158
    • Sever, P.S.1    Dahlof, B.2    Poulter, N.R.3
  • 7
    • 0003491942 scopus 로고    scopus 로고
    • Scottish Intercollegiate Guidelines Network, SIGN publication No 40. Edinburgh: Royal College of Physicians
    • Scottish Intercollegiate Guidelines Network. Lipids and the primary prevention of coronary heart disease. SIGN publication No 40. Edinburgh: Royal College of Physicians.
    • Lipids and the primary prevention of coronary heart disease
  • 8
    • 0032437504 scopus 로고    scopus 로고
    • Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association
    • Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Heart 1998; 80: S1-S29.
    • (1998) Heart , vol.80
  • 10
    • 1542432170 scopus 로고    scopus 로고
    • Guidelines for management of hypertension: Report of the fourth working party of the British Hypertension Society, 2004 - BHS IV
    • Williams B, Poulter NP, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004 - BHS IV. J Hum Hypertens 2004; 18: 139-185.
    • (2004) J Hum Hypertens , vol.18 , pp. 139-185
    • Williams, B.1    Poulter, N.P.2    Brown, M.J.3
  • 11
    • 0037193808 scopus 로고    scopus 로고
    • Resource management in prevention of coronary heart disease: Optimising prescription of lipid-lowering drugs
    • Shepherd J. Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugs. Lancet 2002; 359: 2271-2273.
    • (2002) Lancet , vol.359 , pp. 2271-2273
    • Shepherd, J.1
  • 12
    • 84889436895 scopus 로고    scopus 로고
    • The Tayside Medicines Monitoring Unit (MEMO)
    • 4th edn, Strom BL ed, John Wiley and Sons: Chichester
    • Wei L, Parkinson J, MacDonald TM. The Tayside Medicines Monitoring Unit (MEMO). In Pharmacoepidemiology, 4th edn, Strom BL (ed.). John Wiley and Sons: Chichester, 2005; 323-336.
    • (2005) Pharmacoepidemiology , pp. 323-336
    • Wei, L.1    Parkinson, J.2    MacDonald, T.M.3
  • 13
    • 34247519400 scopus 로고    scopus 로고
    • http://www.pharmacoepi.org/resources/guidelines_08027.cfm
  • 14
    • 0036720351 scopus 로고    scopus 로고
    • Adherence to statin treatment and readmission of patients after myocardial infarction: A six year follow up study
    • Wei L, Wang J, Thompson P, et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002; 88: 229-233.
    • (2002) Heart , vol.88 , pp. 229-233
    • Wei, L.1    Wang, J.2    Thompson, P.3
  • 15
    • 34247469554 scopus 로고    scopus 로고
    • http://www.show.scot.nhs.ukrisdonline/Scottish_Health_Statistics/SHS98/ Appendix.pdf
  • 16
    • 0032032592 scopus 로고    scopus 로고
    • Comparative dose efficacy study of atorvastatin versus sinivastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
    • Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus sinivastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81: 582-587.
    • (1998) Am J Cardiol , vol.81 , pp. 582-587
    • Jones, P.1    Kafonek, S.2    Laurora, I.3    Hunninghake, D.4
  • 17
    • 0038645309 scopus 로고    scopus 로고
    • Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)
    • Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152-160.
    • (2003) Am J Cardiol , vol.92 , pp. 152-160
    • Jones, P.H.1    Davidson, M.H.2    Stein, E.A.3
  • 18
    • 27744473507 scopus 로고    scopus 로고
    • Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: A comparison of methods
    • Zhou Z, Rahme E, Abrahamowicz M, Pilote L. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol 2005; 162: 1016-1023.
    • (2005) Am J Epidemiol , vol.162 , pp. 1016-1023
    • Zhou, Z.1    Rahme, E.2    Abrahamowicz, M.3    Pilote, L.4
  • 19
    • 0036804450 scopus 로고    scopus 로고
    • Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS)
    • Streja L, Packard CJ, Shepherd J, Cobbe S, Ford I. Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol 2002; 90: 731-736.
    • (2002) Am J Cardiol , vol.90 , pp. 731-736
    • Streja, L.1    Packard, C.J.2    Shepherd, J.3    Cobbe, S.4    Ford, I.5
  • 20
    • 0018962999 scopus 로고
    • Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project
    • The Coronary Drug Project Research Group
    • The Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med 1980; 303: 1038-1041.
    • (1980) N Engl J Med , vol.303 , pp. 1038-1041
  • 21
    • 17244372297 scopus 로고
    • Smoking
    • eds, Stationary Office: Edinburgh, Scotland, United Kingdom
    • Turner R. Smoking. In Scotland's Health: Scottish Health Survey 1995, Vol 1, Dong W, Erins B (eds). Stationary Office: Edinburgh, Scotland, United Kingdom, 1997: 140-141.
    • (1995) Scotland's Health: Scottish Health Survey , vol.1 , pp. 140-141
    • Turner, R.1
  • 22
    • 0033928767 scopus 로고    scopus 로고
    • Socio-economic status, obesity and prevalence of Type 1 and Type 2 diabetes mellitus
    • Evans JM, Newton RW, Ruta DA, MacDonald TM, Morris AD. Socio-economic status, obesity and prevalence of Type 1 and Type 2 diabetes mellitus. Diabet Med. 2000; 17: 478-480.
    • (2000) Diabet Med , vol.17 , pp. 478-480
    • Evans, J.M.1    Newton, R.W.2    Ruta, D.A.3    MacDonald, T.M.4    Morris, A.D.5
  • 23
    • 0030716411 scopus 로고    scopus 로고
    • Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: Cohort study
    • MacDonald TM, Morant SV, Robinson GC, et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997; 315: 1333-1337.
    • (1997) BMJ , vol.315 , pp. 1333-1337
    • MacDonald, T.M.1    Morant, S.V.2    Robinson, G.C.3
  • 24
    • 11144355354 scopus 로고    scopus 로고
    • Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    • Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1505.
    • (2004) N Engl J Med , vol.350 , pp. 1495-1505
    • Cannon, C.P.1    Braunwald, E.2    McCabe, C.H.3
  • 25
    • 15944410609 scopus 로고    scopus 로고
    • Intensive lipid lowering with atorvastatin in patients with stable coronary disease
    • LaRosa J, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435.
    • (2005) N Engl J Med , vol.352 , pp. 1425-1435
    • LaRosa, J.1    Grundy, S.M.2    Waters, D.D.3
  • 26
    • 19644401171 scopus 로고    scopus 로고
    • Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease
    • Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141: 764-770.
    • (2004) Ann Intern Med , vol.141 , pp. 764-770
    • Wei, L.1    MacDonald, T.M.2    Walker, B.R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.